Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Aclaris Therapeutics Inc. (NASDAQ : ACRS) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Quote
| Last: | $4.36 |
|---|---|
| Change Percent: | -4.91% |
| Open: | $4.69 |
| Close: | $4.585 |
| High: | $4.7 |
| Low: | $4.35 |
| Volume: | 254,794 |
| Last Trade Date Time: | 06/05/2026 12:43:29 pm |
Stock Data
| Market Cap: | $404,127,741 |
|---|---|
| Float: | 76,708,429 |
| Insiders Ownership: | 1.82% |
| Institutions: | 41 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.aclaristx.com |
| Country: | US |
| City: | Wayne |
Recent News Releases
Subscribe to Our Newsletter
Message Board Posts
investorshub : glenn1919
investorshub : glenn1919
investorshub : INV4
investorshub : INV4
**MWN-AI FAQ is based on asking OpenAI questions about Aclaris Therapeutics Inc. (NASDAQ: ACRS).
